KR20100117123A - Ｅｒｋ 억제제인 화합물 - Google Patents
Ｅｒｋ 억제제인 화합물 Download PDFInfo
- Publication number
- KR20100117123A KR20100117123A KR1020107020896A KR20107020896A KR20100117123A KR 20100117123 A KR20100117123 A KR 20100117123A KR 1020107020896 A KR1020107020896 A KR 1020107020896A KR 20107020896 A KR20107020896 A KR 20107020896A KR 20100117123 A KR20100117123 A KR 20100117123A
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- group
- triazolyl
- compound
- nitrogen
- Prior art date
Links
- 0 CC(C)Oc(cc1)ncc1-c1n[n]c2ccc(*C#C)cc12 Chemical compound CC(C)Oc(cc1)ncc1-c1n[n]c2ccc(*C#C)cc12 0.000 description 9
- JESQTEITRAROJF-NSCUHMNNSA-N C/C=C/COc1ncc(CS)cc1 Chemical compound C/C=C/COc1ncc(CS)cc1 JESQTEITRAROJF-NSCUHMNNSA-N 0.000 description 1
- CDCDDZSGOBDDFZ-ARJAWSKDSA-N C/C=C\N(CCO)N=C Chemical compound C/C=C\N(CCO)N=C CDCDDZSGOBDDFZ-ARJAWSKDSA-N 0.000 description 1
- DYGIEZVQDSRKIL-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC=C1c1ncc(-c2n[n](C)cn2)[s]1)=O Chemical compound CC(C)(C)OC(N(CC1)CC=C1c1ncc(-c2n[n](C)cn2)[s]1)=O DYGIEZVQDSRKIL-UHFFFAOYSA-N 0.000 description 1
- TZJKZROVUFJSSX-DNUYPZOSSA-N CC(C)Oc(nc1)ccc1-c(c1c2)n[nH]c1ccc2NC([C@]1(CC(CC(N(CC2)CC=C2c2ncc(C3=NN(C)C=CCC3)[s]2)=O)CC1)OC)=O Chemical compound CC(C)Oc(nc1)ccc1-c(c1c2)n[nH]c1ccc2NC([C@]1(CC(CC(N(CC2)CC=C2c2ncc(C3=NN(C)C=CCC3)[s]2)=O)CC1)OC)=O TZJKZROVUFJSSX-DNUYPZOSSA-N 0.000 description 1
- WCHJIRHBNHJGJF-NRFANRHFSA-N CC(C)Oc(nc1)ccc1-c1n[nH]c(cc2)c1cc2NC([C@]1(CNCC1)OC)=O Chemical compound CC(C)Oc(nc1)ccc1-c1n[nH]c(cc2)c1cc2NC([C@]1(CNCC1)OC)=O WCHJIRHBNHJGJF-NRFANRHFSA-N 0.000 description 1
- BSTMTTUJWDJCEN-UHFFFAOYSA-N CC(C)Oc1cc(-c(c2cc([N+]([O-])=O)ccc22)n[n]2[Tl])ccn1 Chemical compound CC(C)Oc1cc(-c(c2cc([N+]([O-])=O)ccc22)n[n]2[Tl])ccn1 BSTMTTUJWDJCEN-UHFFFAOYSA-N 0.000 description 1
- SGDLESHDPULJNT-UHFFFAOYSA-N CC(C)Oc1nccc(S)c1 Chemical compound CC(C)Oc1nccc(S)c1 SGDLESHDPULJNT-UHFFFAOYSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- QPLYDKMORWCFIR-UHFFFAOYSA-N CC1(C)OB(C(CC2)=CCN2Br)OC1(C)C Chemical compound CC1(C)OB(C(CC2)=CCN2Br)OC1(C)C QPLYDKMORWCFIR-UHFFFAOYSA-N 0.000 description 1
- CAMBLNIEZFINIF-KTKRTIGZSA-N CCC(C(C)SCC)/C(/C)=C\N(C)NC Chemical compound CCC(C(C)SCC)/C(/C)=C\N(C)NC CAMBLNIEZFINIF-KTKRTIGZSA-N 0.000 description 1
- ZCINCPRIYVCTGQ-UHFFFAOYSA-N CCN(CC1)CC1(C(OC)=O)SC Chemical compound CCN(CC1)CC1(C(OC)=O)SC ZCINCPRIYVCTGQ-UHFFFAOYSA-N 0.000 description 1
- SKFQJMAGPTUFEW-UHFFFAOYSA-N CCOC(c(cc1)ccc1Br)=N Chemical compound CCOC(c(cc1)ccc1Br)=N SKFQJMAGPTUFEW-UHFFFAOYSA-N 0.000 description 1
- GEGOSBPKDSOSGF-UHFFFAOYSA-N COC(C1(CNCC1)SC)=O Chemical compound COC(C1(CNCC1)SC)=O GEGOSBPKDSOSGF-UHFFFAOYSA-N 0.000 description 1
- MVOLCNBBORUMLK-UHFFFAOYSA-N CS(C)Cc(cc1)ccc1-c1n[n](CCO)cn1 Chemical compound CS(C)Cc(cc1)ccc1-c1n[n](CCO)cn1 MVOLCNBBORUMLK-UHFFFAOYSA-N 0.000 description 1
- MWZDIEIXRBWPLG-UHFFFAOYSA-N C[n]1ncnc1 Chemical compound C[n]1ncnc1 MWZDIEIXRBWPLG-UHFFFAOYSA-N 0.000 description 1
- YYKVYBTZELPZEU-UHFFFAOYSA-N Cc1ncc(-c2n[n](C)cn2)[s]1 Chemical compound Cc1ncc(-c2n[n](C)cn2)[s]1 YYKVYBTZELPZEU-UHFFFAOYSA-N 0.000 description 1
- HQSCPPCMBMFJJN-UHFFFAOYSA-N N#Cc(cc1)ccc1Br Chemical compound N#Cc(cc1)ccc1Br HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 1
- UKANTTYEQYBLGO-UHFFFAOYSA-N OC(CN1CC2(CC2)CC1)=O Chemical compound OC(CN1CC2(CC2)CC1)=O UKANTTYEQYBLGO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3040708P | 2008-02-21 | 2008-02-21 | |
| US61/030,407 | 2008-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100117123A true KR20100117123A (ko) | 2010-11-02 |
Family
ID=40601237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107020896A KR20100117123A (ko) | 2008-02-21 | 2009-02-19 | Ｅｒｋ 억제제인 화합물 |
Country Status (23)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| KR20080103996A (ko) | 2006-02-16 | 2008-11-28 | 쉐링 코포레이션 | Ｅｒｋ 억제제로서 피롤리딘 유도체 |
| US8586543B2 (en) | 2008-08-19 | 2013-11-19 | Merck Sharp & Dohme Corp. | IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors |
| US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
| WO2011002887A1 (en) | 2009-07-02 | 2011-01-06 | Schering Corporation | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS |
| EP2483263B1 (en) | 2009-09-30 | 2018-07-18 | Merck Sharp & Dohme Corp. | Heterocyclic compounds that are erk inhibitors |
| WO2011163330A1 (en) * | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP2615916B1 (en) * | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| EP2630133A1 (de) | 2010-10-22 | 2013-08-28 | Bayer Intellectual Property GmbH | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
| WO2012068148A1 (en) * | 2010-11-16 | 2012-05-24 | Medimmune, Llc | Regimens for treatments using anti-igf antibodies |
| US9000209B2 (en) | 2011-07-22 | 2015-04-07 | Iowa State University Research Foundation, Inc. | Method of regioselective synthesis of substituted benzoates |
| ES2857649T3 (es) | 2012-03-01 | 2021-09-29 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| CA2872110C (en) | 2012-07-18 | 2019-08-06 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in drugs |
| RU2660429C2 (ru) * | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
| WO2014052566A1 (en) * | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| CA3005118A1 (en) * | 2013-03-13 | 2014-09-18 | F. Hoffmann-La Roche Ag | Process for making benzoxazepin compounds |
| US8871966B2 (en) | 2013-03-15 | 2014-10-28 | Iowa State University Research Foundation, Inc. | Regiospecific synthesis of terephthalates |
| EA032196B1 (ru) | 2013-10-03 | 2019-04-30 | Кура Онколоджи, Инк. | Ингибиторы erk и способы применения |
| US10428387B2 (en) | 2014-05-16 | 2019-10-01 | University Of Massachusetts | Treating chronic myelogenous leukemia (CML) |
| WO2016025639A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a chemotherapeutic agent and related methods |
| WO2016095089A1 (en) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| WO2016095088A1 (en) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| AU2015362844B2 (en) | 2014-12-18 | 2019-10-24 | Merck Sharp & Dohme Corp. | (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations |
| BR112017012558A2 (pt) | 2014-12-19 | 2018-01-02 | Merck Sharp & Dohme | Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas |
| AU2016242940B2 (en) * | 2015-04-03 | 2020-11-05 | Recurium Ip Holdings, Llc | Spirocyclic compounds |
| US20180250232A1 (en) * | 2015-09-03 | 2018-09-06 | Merck Sharp & Dohme Corp. | Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations |
| CN106432182B (zh) * | 2016-09-06 | 2019-04-30 | 铜仁学院 | 特地唑胺中间体的合成方法 |
| CN109020789B (zh) * | 2017-06-12 | 2021-08-13 | 浙江医药股份有限公司新昌制药厂 | 一种制备2-甲氧基丙烯的方法 |
| WO2021067266A1 (en) * | 2019-10-01 | 2021-04-08 | Recurium Ip Holdings, Llc | Pyrrolidinyl-based compounds |
| EP4041393A1 (en) | 2019-10-09 | 2022-08-17 | Bayer Aktiengesellschaft | Novel heteroaryl-triazole compounds as pesticides |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| EP0934270A1 (en) | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
| GB2323845A (en) | 1997-03-31 | 1998-10-07 | Merck & Co Inc | MEK inhibiting lactones |
| DE69841434D1 (de) | 1997-07-18 | 2010-02-25 | Novo Nordisk Healthcare Ag | VERWENDUNG VON FVIIa ODER FVIIAi ZUR BEHANDLUNG VON ENDOTHELIALER FEHLFUNKTION BZW ZUR INHIBIERUNG DER ANGIOGENESE |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| SK14082001A3 (sk) | 2000-02-05 | 2002-03-05 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje |
| AU2001236720A1 (en) | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
| MXPA02008103A (es) | 2000-03-15 | 2002-11-29 | Warner Lambert Co | Diarilaminas sustituidas con 5-amida como inhibidores mek. |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| EP1318997B1 (en) | 2000-09-15 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002022610A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use as inhibitors of erk |
| EP1353905B1 (en) * | 2000-11-20 | 2007-01-10 | Scios Inc. | Piperidine/piperazine-type inhibitors of p38 kinase |
| IL156368A0 (en) | 2000-12-21 | 2004-01-04 | Vertex Pharma | Pyrazole derivatives and pharmaceutical compositions containing the same |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| CA2440842A1 (en) * | 2001-04-16 | 2002-10-24 | Eisai Co., Ltd. | Novel 1h-indazole compounds |
| US6962936B2 (en) | 2001-04-27 | 2005-11-08 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
| AU2002305260A1 (en) | 2001-04-27 | 2002-11-11 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
| WO2003011854A1 (en) | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
| DE60226154T2 (de) | 2001-08-03 | 2009-05-20 | Vertex Pharmaceuticals Inc., Cambridge | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
| WO2003035626A2 (en) | 2001-10-23 | 2003-05-01 | Applied Research Systems Ars Holding N.V. | Azole derivatives and pharmaceutical compositions containing them |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| WO2003099212A2 (en) | 2002-05-24 | 2003-12-04 | The University Of Utah Research Foundation | Mitogen activated protein kinase inhibitor compositions for lymphoma therapy |
| AU2003241925A1 (en) * | 2002-05-31 | 2003-12-19 | Eisai R&D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| AR041291A1 (es) | 2002-09-19 | 2005-05-11 | Schering Corp | Imidazopiridinas como inhibidores de quinasa dependientes de ciclina |
| EP1606284B1 (en) | 2003-03-13 | 2009-12-02 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
| EP1791831A4 (en) * | 2003-11-19 | 2009-07-08 | Signal Pharm Llc | METHOD FOR THE TREATMENT OF DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES |
| WO2005063258A1 (en) | 2003-12-22 | 2005-07-14 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| JP2007530595A (ja) | 2004-03-26 | 2007-11-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋ２のピリジンインヒビターおよびそれらの使用 |
| JP2007532615A (ja) | 2004-04-13 | 2007-11-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| JP4993604B2 (ja) | 2004-05-14 | 2012-08-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピロリルピリミジンｅｒｋプロテインキナーゼインヒビターのプロドラッグ |
| ES2897422T3 (es) | 2004-05-14 | 2022-03-01 | Vertex Pharma | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
| EP1833820A1 (en) | 2004-12-23 | 2007-09-19 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of erk protein kinase and uses therof |
| CN100377868C (zh) * | 2005-03-24 | 2008-04-02 | 中国科学院物理研究所 | 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途 |
| WO2006136008A1 (en) | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
| US8217042B2 (en) * | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| US8546404B2 (en) * | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| RS51981B (en) * | 2005-12-13 | 2012-02-29 | Schering Corporation | POLYCYCLIC INDASOL DERIVATIVES WHICH ARE ERK INHIBITORS |
| KR20080103996A (ko) * | 2006-02-16 | 2008-11-28 | 쉐링 코포레이션 | Ｅｒｋ 억제제로서 피롤리딘 유도체 |
| EP2260869A3 (en) * | 2006-04-20 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Pharmaceutical product |
| US7601852B2 (en) * | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
| BRPI0713119A2 (pt) * | 2006-06-30 | 2012-04-17 | Schering Corp | piperidinas substituìdas que aumentam a atividade de p53 e os usos destas |
| US7671832B2 (en) * | 2006-07-10 | 2010-03-02 | Philips Lumileds Lighting Company, Llc | Multi-colored LED backlight with color-compensated clusters near edge |
| CA3001152A1 (en) | 2007-03-28 | 2008-10-09 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| JP2010529122A (ja) * | 2007-06-05 | 2010-08-26 | シェーリング コーポレイション | 多環式インダゾール誘導体および癌の治療のためのｅｒｋ阻害剤としてのそれらの使用 |
| JP5451602B2 (ja) | 2007-06-08 | 2014-03-26 | アッヴィ・インコーポレイテッド | キナーゼ阻害薬としての５−ヘテロアリール置換インダゾール類 |
| CA2691417A1 (en) | 2007-06-18 | 2008-12-24 | Schering Corporation | Heterocyclic compounds and use thereof as erk inhibitors |
| EP2483263B1 (en) | 2009-09-30 | 2018-07-18 | Merck Sharp & Dohme Corp. | Heterocyclic compounds that are erk inhibitors |
-
2009
- 2009-02-19 WO PCT/US2009/034447 patent/WO2009105500A1/en active Application Filing
- 2009-02-19 CA CA2714479A patent/CA2714479A1/en not_active Abandoned
- 2009-02-19 NZ NZ587504A patent/NZ587504A/xx not_active IP Right Cessation
- 2009-02-19 SG SG2013013206A patent/SG188179A1/en unknown
- 2009-02-19 US US12/918,099 patent/US8716483B2/en active Active
- 2009-02-19 MX MX2010009268A patent/MX2010009268A/es active IP Right Grant
- 2009-02-19 RU RU2010138635/04A patent/RU2525389C2/ru not_active IP Right Cessation
- 2009-02-19 BR BRPI0908120A patent/BRPI0908120A8/pt not_active IP Right Cessation
- 2009-02-19 KR KR1020107020896A patent/KR20100117123A/ko not_active Application Discontinuation
- 2009-02-19 MY MYPI20103904 patent/MY152271A/en unknown
- 2009-02-19 JP JP2010547732A patent/JP5276676B2/ja not_active Expired - Fee Related
- 2009-02-19 EP EP09712601.5A patent/EP2260031B1/en active Active
- 2009-02-19 AU AU2009215534A patent/AU2009215534B8/en not_active Ceased
- 2009-02-19 ES ES09712601.5T patent/ES2556353T3/es active Active
- 2009-02-19 CN CN200980113870.7A patent/CN102015693B/zh not_active Expired - Fee Related
- 2009-02-20 PE PE2009000250A patent/PE20091491A1/es active IP Right Grant
- 2009-02-20 AR ARP090100604A patent/AR070460A1/es active IP Right Grant
- 2009-02-20 CL CL2009000394A patent/CL2009000394A1/es unknown
- 2009-02-20 TW TW098105537A patent/TWI398441B/zh not_active IP Right Cessation
-
2010
- 2010-08-10 IL IL207530A patent/IL207530A/en active IP Right Grant
- 2010-08-18 ZA ZA2010/05909A patent/ZA201005909B/en unknown
- 2010-08-20 EC EC2010010415A patent/ECSP10010415A/es unknown
- 2010-09-21 CO CO10116702A patent/CO6300939A2/es active IP Right Grant
-
2014
- 2014-01-17 ZA ZA2014/00396A patent/ZA201400396B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2260031B1 (en) | Compounds that are erk inhibitors | |
| EP2483263B1 (en) | Heterocyclic compounds that are erk inhibitors | |
| EP1984331B1 (en) | Pyrrolidine derivatives as erk inhibitors | |
| EP1966151B1 (en) | Polycyclic indazole derivatives that are erk inhibitors | |
| US20110038876A1 (en) | Heterocyclic compounds and use thereof as erk inhibitors | |
| US8546404B2 (en) | Compounds that are ERK inhibitors | |
| AU2008262412A1 (en) | Polycyclic indazole derivatives and their use as ERK inhibitors for the treatment of cancer | |
| JP2009523799A (ja) | ファルネシルタンパク質トランスフェラーゼインヒビターとしてのピペラジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |